p57 Kip2 Antibody - #AF6819

(3)   (4)  
Product: p57 Kip2 Antibody
Catalog: AF6819
Description: Rabbit polyclonal antibody to p57 Kip2
Application: WB
Reactivity: Human
Mol.Wt.: 32kD(Calculated).
Uniprot: P49918
RRID: AB_2847542

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors
Related Downloads
MSDS
Data Sheet
COA
Protocols
WB Handbook
IHC Protocol
IF/ICC Protocol

Product Info

Source:
Rabbit
Application:
WB 1:500-1:2000
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human
Clonality:
Polyclonal
Specificity:
p57 Kip2 Antibody detects endogenous levels of total p57 Kip2.
RRID:
AB_2847542
Cite Format: Affinity Biosciences Cat# AF6819, RRID:AB_2847542.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

Beckwith Wiedemann syndrome; BWCR; BWS; CDKI; CDKN 1C; CDKN1C; CDN1C_HUMAN; Cyclin dependent kinase inhibitor 1C; Cyclin dependent kinase inhibitor p57; Cyclin-dependent kinase inhibitor 1C; Cyclin-dependent kinase inhibitor p57; KIP 2; KIP2; p57; p57 Kip 2; p57KIP2; WBS;

Immunogens

Immunogen:

A synthesized peptide derived from human p57 Kip2.

Uniprot:

P49918(CDN1C_HUMAN) >>Visit HPA database.

Gene(ID):
CDKN1C(1028)
Expression:
P49918 CDN1C_HUMAN:

Expressed in the heart, brain, lung, skeletal muscle, kidney, pancreas and testis. Expressed in the eye. High levels are seen in the placenta while low levels are seen in the liver.

Sequence:
MSDASLRSTSTMERLVARGTFPVLVRTSACRSLFGPVDHEELSRELQARLAELNAEDQNRWDYDFQQDMPLRGPGRLQWTEVDSDSVPAFYRETVQVGRCRLLLAPRPVAVAVAVSPPLEPAAESLDGLEEAPEQLPSVPVPAPASTPPPVPVLAPAPAPAPAPVAAPVAAPVAVAVLAPAPAPAPAPAPAPAPVAAPAPAPAPAPAPAPAPAPAPDAAPQESAEQGANQGQRGQEPLADQLHSGISGRPAAGTAAASANGAAIKKLSGPLISDFFAKRKRSAPEKSSGDVPAPCPSPSAAPGVGSVEQTPRKRLR

PTMs - P49918 As Substrate

Site PTM Type Enzyme
S43 Phosphorylation
S146 Phosphorylation Q16539 (MAPK14)
K266 Acetylation
S268 Phosphorylation
K278 Acetylation
S282 Phosphorylation P31749 (AKT1)
S297 Phosphorylation
S299 Phosphorylation
S306 Phosphorylation
T310 Phosphorylation P31749 (AKT1)

Research Backgrounds

Function:

Potent tight-binding inhibitor of several G1 cyclin/CDK complexes (cyclin E-CDK2, cyclin D2-CDK4, and cyclin A-CDK2) and, to lesser extent, of the mitotic cyclin B-CDC2. Negative regulator of cell proliferation. May play a role in maintenance of the non-proliferative state throughout life.

Subcellular Location:

Nucleus.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Expressed in the heart, brain, lung, skeletal muscle, kidney, pancreas and testis. Expressed in the eye. High levels are seen in the placenta while low levels are seen in the liver.

Subunit Structure:

Interacts with PCNA.

Family&Domains:

Belongs to the CDI family.

Research Fields

· Cellular Processes > Cell growth and death > Cell cycle.   (View pathway)

References

1). GCNT4 is Associated with Prognosis and Suppress Cell Proliferation in Gastric Cancer. OncoTargets and Therapy (PubMed: 32922038) [IF=4.0]

Application: WB    Species: Human    Sample: gastric cancer cell

Figure 5 Overexpression of GCNT4 inhibits GC cell growth. (A) GCNT4 baseline mRNA and protein expression levels in 5 gastric cancer cell lines and one normal gastric epithelial cell line (GES-1) by RT-qPCR (upper panel) and Western blotting (down panel); (mean±SD, with one-way ANOVA). (B) The efficiency of GCNT4 overexpression were validated by qRT–PCR (upper panel) and Western blotting (down panel) in SGC-7901 and MGC-803 (mean±SD, with paired t-test); P<0.001. (C) CCK-8 assay showing GCNT4 overexpression inhibited SGC7901 and MGC-803 proliferation compared with control cells (mean±SD, with paired t-test); *P<0.01. (D) A flow cytometry assays showing GCNT4 overexpression arrested SGC-7901 and MGC-803 cell cycle at G2/M phase. (E) Western-blot analysis for the protein level of indicated molecules in GCNT4-overexpressing SGC-7901 and MGC-803 for 48 hours.
2). Long non-coding RNA NEAT1 regulates E2F3 expression by competitively binding to miR-377 in non-small cell lung cancer. Oncology Letters (PubMed: 29085511) [IF=2.9]

Application: WB    Species: human    Sample: A549 cells

Figure 4.| E2F3 promotes NSCLC proliferation through regulating the cell cycle in NSCLC. The expression of cell cycle‑associated proteins in A549 were detected by western blot (A). E2F3 can rescue the cell growth inhibition induced by decreased NEAT1 (B). P<0.05.
3). Hsa-miR-326 targets CCND1 and inhibits non-small cell lung cancer development. Oncotarget (PubMed: 26840018)

Application: WB    Species:    Sample:

(G–H) Expression of cyclin D1, cyclin D1, CDK4, p21 and p57 protein in transfected A549 and SPC-A-1 cells. Assays were performed in triplicate. Means ± SEM was shown. Statistical analysis was conducted using student t-test.

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.